Congratulations to @ProfRScolyerMIA for his 2023 Society For Melanoma Research life time achievement award. Standing ovation from the room. Melanoma Institute Australia Professor Georgina Long AO (Bluesky @gvlongphdmd) @amenzies9

Fabulous data on #uveal #melanoma - great tumour reduction in ph1 #clinical #trial of DYP688 presented by colleague from Melanoma Institute Australia - Matteo Carlino Society For Melanoma Research. Responses seen and so far, durable!

Great study to be involved with. Novel design of ADC delivered targeted therapy, hopefully the first of many in melanoma and beyond.

Team from Melanoma Institute Australia gave superb world stage preso’s at #SMR2023 in #Philadelphia including Professor Georgina Long AO (Bluesky @gvlongphdmd) keynote address on progress & future prospects 4 curing #melanoma, Matteo Carlino on uveal melanoma & Tuba Gide on #immunotherapy response predictors! Proud of amazing team!

Congratulations

We welcome Fed Govt's anncmnt today for funding of additional 100 #CancerNurses, in addition to 35 national melanoma nurses program already underway at MIA. We look forward to partnership with Govt & Mcgrathfdn to ensure melanoma expertise is broadened across all cancer nurses.

Our newest collaboration with @amenzies9 Adriana Hepner Matteo Carlino @mcquadeMDLAc @alexshoushtari etc. is online. Insights into acquired resistance to anti-PD-1 based therapy for melanoma. Further treatment with IO-based strategies led to best outcomes. authors.elsevier.com/c/1i7Pz3QE--VL…

It is time for this to change. I know NSW Health and Chris Minns can do this. Those that need care and work in Western Sydney deserve better. The elastic band is about to break. smh.com.au/national/nsw/t…

A clinical trial, developed by MIA in collaboration with int’l colleagues, has been named by Nature Medicine as one of 11 clinical trials that will shape medicine in 2024. #NADINA clinical trial investigating if #neoadjuvant (pre-surgery) combination #immunotherapy is more

So proud of our work The Netherlands Cancer Institute Melanoma Institute Australia for #Nadina trial. #neoadjuvant #checkpoint #immunotherapy 68% decrease risk of progression/recurrence & death vs adjuvant anti-pd1. Multidisciplinary teamwork-great for patients with macroscopic stage 3 melanoma. Published today in NEJM

I’m confident you will be done by 80!

I went through my workday with a heavy heart. I can’t believe you, my work partner, are not right down the hall to talk science,review patient cases,offer me strategic advice or your favorite restaurant recs.Our team will keep fighting melanoma as you would wish. Rest easy.

IBI363 PD-1/IL2α bispecific FDA Fast Track Designation for Advanced/Metastatic #Melanoma (DCR) 73.0%. Among 8 immuno-oncology (IO)–naive patients with #mucosalmelanoma, ORR was 75.0%, including 1 CR and 5 PRs. The DCR in this population was 100%. Innovent Melanoma Research Foundation

$IDYA IDEAYA has been recommended to move forward with a dose in Part 2a of the trial combining Darovasertib and Crizotinib in Metastatic Uveal Melanoma. More Info: pryzm.ozmosi.com/product/21251 $XBI $IBB $XPH $PPH

Another important analysis led by Matteo Carlino featuring contributions from our team Perlmutter Cancer Center at NYU Langone Health. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma pubmed.ncbi.nlm.nih.gov/39667250/

I enjoyed working with this team to publish our experience in skin toxicities from cancer immunotherapy. NYU Grossman School of Medicine Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors pubmed.ncbi.nlm.nih.gov/40072456/

NSW government walks back claims of cancelled chemotherapy appointments during doctors' strike NSW doctor strike 9news.com.au/national/nsw-g…

Good to know the apologised to the media outlets. Never mind the clinicians they lied about

My personal selection of the high yield abstracts for melanoma that will be presented at ASCO 2025! ASCO #ASCO25

Happening now at #ASCO25: Matteo Carlino, MD (@mattcarlino) from Melanoma Institute Australia, shares results from a melanoma rapid oral abstract session on DYP688 in metastatic uveal #melanoma. ➡️ First ADC-delivered payload to show efficacy in met uveal melanoma ➡️ Favorable